Media headlines about Histogenics (NASDAQ:HSGX) have been trending somewhat positive on Friday, according to Accern. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Histogenics earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.6151324089296 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Histogenics stock lose nearly three-fourths of its value after Phase 3 trial on knee damage treatment fails (proactiveinvestors.com)
- Histogenics (HSGX) Reports Top-Line Results from Phase 3 Clinical Trial of NeoCart in Patients with Knee Cartilage Damage (streetinsider.com)
- Needham & Company LLC Boosts Histogenics (HSGX) Price Target to $5.00 (americanbankingnews.com)
- Histogenics Corp (HSGX) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Histogenics (HSGX) Stock Rating Lowered by BTIG Research (americanbankingnews.com)
HSGX stock traded up $0.01 during midday trading on Friday, hitting $0.71. The company’s stock had a trading volume of 2,424,900 shares, compared to its average volume of 247,143. The stock has a market capitalization of $22.22 million, a PE ratio of -0.72 and a beta of 1.70. Histogenics has a 12 month low of $0.67 and a 12 month high of $3.35.
HSGX has been the topic of several analyst reports. ValuEngine raised Histogenics from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 price objective on shares of Histogenics in a research report on Monday, August 13th. Brookline Cap M reaffirmed a “buy” rating on shares of Histogenics in a research report on Wednesday, August 1st. Needham & Company LLC upped their price objective on Histogenics to $5.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Zacks Investment Research cut Histogenics from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Histogenics presently has a consensus rating of “Buy” and a consensus price target of $3.45.
Histogenics Company Profile
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Recommended Story: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.